Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?
about
Breast cancer susceptibility gene 1 (BRCA1) predict clinical outcome in platinum- and toxal-based chemotherapy in non-small-cell lung cancer (NSCLC) patients: a system review and meta-analysisFine tuning chemotherapy to match BRCA1 statusEnhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells.Profiles of genomic instability in high-grade serous ovarian cancer predict treatment outcomeDifferential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review.Role of BRCA Mutations in the Modulation of Response to Platinum Therapy.
P2860
Can the status of the breast and ovarian cancer susceptibility gene 1 product (BRCA1) predict response to taxane-based cancer therapy?
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on June 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Can the status of the breast a ...... o taxane-based cancer therapy?
@en
Can the status of the breast and ovarian cancer susceptibility gene 1 product
@nl
type
label
Can the status of the breast a ...... o taxane-based cancer therapy?
@en
Can the status of the breast and ovarian cancer susceptibility gene 1 product
@nl
prefLabel
Can the status of the breast a ...... o taxane-based cancer therapy?
@en
Can the status of the breast and ovarian cancer susceptibility gene 1 product
@nl
P2093
P2860
P1476
Can the status of the breast a ...... o taxane-based cancer therapy?
@en
P2093
Aneliya Velkova
Diego A R Zorio
J Thomas De Ligio
P2860
P304
P356
10.2174/187152009788451798
P577
2009-06-01T00:00:00Z